

Article

Nutritional, Antioxidant, Antimicrobial, and Anticholinesterase Properties of *Phyllanthus emblica*: A Study Supported by Spectroscopic and Computational Investigations

Mohamed A. A. Orabi ^{1,*}, Aso Hameed Hasan ^{2,3}, Sameh F. AbouZid ⁴, Dalia El Amir ^{4,*}, Mona H. Hetta ⁵, Ahmed Abdullah Al Awadh ⁶, Omaish Salman Alqahtani ¹, Tsutomu Hatano ⁷ and Mohamed A. El-Shanawany ⁸

¹ Department of Pharmacognosy, College of Pharmacy, Najran University, Najran 66454, Saudi Arabia; osalqahtani@nu.edu.sa

² Department of Chemistry, College of Science, University of Garmian, Kalar 46021, Kurdistan Region, Iraq; aso.hameed@garmian.edu.krd

³ Department of Chemistry, Faculty of Science, Universiti Teknologi Malaysia, Johor Bahru 81310, Johor, Malaysia

⁴ Department of Pharmacognosy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt; sameh.zaid@pharm.bsu.edu.eg

⁵ Department of Pharmacognosy, Faculty of Pharmacy, Fayoum University, Fayoum 63514, Egypt; monahetta@gmail.com

⁶ Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Najran University, Najran 66454, Saudi Arabia; aaalawadh@nu.edu.sa

⁷ Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Tsushima, Okayama 700-8530, Japan; hatano-t@cc.okayama-u.ac.jp

⁸ Department of Pharmacognosy, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City 11829, Egypt; mohamed.elshanawani@pharm.aun.edu.eg

* Correspondence: mohamedorabi@azhar.edu.eg or maorabi@nu.edu.sa (M.A.A.O.); dalia.elamir@pharm.bsu.edu.eg (D.E.A.)



Citation: Orabi, M.A.A.; Hasan, A.H.; AbouZid, S.F.; El Amir, D.; Hetta, M.H.; Awadh, A.A.A.; Alqahtani, O.S.; Hatano, T.; El-Shanawany, M.A.

Nutritional, Antioxidant, Antimicrobial, and Anticholinesterase Properties of *Phyllanthus emblica*: A Study Supported by Spectroscopic and Computational Investigations.

Metabolites **2023**, *13*, 1013. <https://doi.org/10.3390/metabo13091013>

Academic Editors: Sameh S. Elhady, Enas E. Eltamany, Timothy O'Toole and Wolfgang Eisenreich

Received: 20 July 2023

Revised: 30 August 2023

Accepted: 11 September 2023

Published: 14 September 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Dietary fruits and vegetables play a vital role as food and drugs and are the main sources of antioxidant defences against degenerative diseases, such as brain dysfunctions, cardiovascular diseases, immune system deteriorations, and cancers, brought on by oxidative damage. *Phyllanthus emblica* is a significant herbal remedy used in conventional medicine to recover lost strength and power. In this research, the potential value of *Phyllanthus emblica* as a food and drug is researched. The total phenolic, total flavonoid, and total tannin contents as well as the nutritional value, vitamin C, vitamin E, and mineral contents of different organs of *P. emblica* were evaluated. The antioxidant and antimicrobial activities of extracts and fractions of different organs of *P. emblica* were determined. A total of eleven flavonoids, simple phenolic, tannin-related phenolic, and tannin molecules were isolated from a hydroalcoholic extract of the leaves and fruits. The structures were identified by spectroscopic data and comparison with the literature values as gallic acid (**1**), naringenin 7-*O*-(6''-*O*-galloyl)- β -D-glucopyranoside (**2**), 3,3'-di-*O*-methyl ellagic acid-4'-*O*- β -D-glucopyranoside (**3**), 1-*O*-galloyl glycerol (**4**), 1,6-di-*O*-galloyl- β -D-glucopyranoside (**5**), flavogallonic acid bislactone (**6**), corilagin (**7**), ethyl gallate (**8**), urolithin M5 (**9**), (*E*)-*p*-coumaroyl-1-*O*- β -D-glucopyranoside (**10**), and 1,2,4,6-tetra-*O*-galloyl- β -D-glucopyranoside (**11**). Among them, compounds **3** and **10** are first isolated from the plant. Molecular docking was performed to investigate the comparative interactions between positive controls (galantamine and donepezil) and selected compounds utilizing acetylcholinesterase (4EY7) as a target receptor. Results exhibited the potency of these compounds against the target receptor. In summary, *P. emblica* has a wealth of minerals, vitamins C and E, and polyphenolic phytochemicals that may work together to treat infectious disease, prevent and/or treat oxidative-damage-related illnesses including Alzheimer's disease.

Keywords: antioxidant; antimicrobial; antiacetylcholinesterase; *Phyllanthus emblica*; polyphenols; nutrition; molecular docking

1. Introduction

Environmental radiation and the oxidant byproducts of regular metabolism seriously damage the DNA, protein, and lipid biomolecules. This damage plays a significant role in the development of degenerative illnesses such as brain dysfunctions, cardiovascular diseases, immune system deterioration, and cancers. Millions of people worldwide are now affected by neurological diseases such as Alzheimer's and dementia. Even though there are treatments, they rarely provide the intended therapeutic effects. As a result, many research teams have been trying to come up with an innovative approach for treating these ailments. Dietary fruits and vegetables play a vital role as food and drugs and are the main sources of antioxidant defenses against these damages. *Phyllanthus emblica* L. (Phyllanthaceae), also known as Amla, Amlaki, or Indian Gooseberry, is widely distributed throughout tropical and subtropical regions including Pakistan, Uzbekistan, Sri Lanka, Southeast Asia, China, and Malaysia [1]. It is native to India and has a hallowed position in Ayurveda; all parts of the plant are used in herbal remedies to restore lost strength and vitality and as medicine [2,3]. *P. emblica* is an important source of vitamin C, amino acids, and minerals [4]. It produces tannins, curcuminoids, flavonoids, triterpenes, fatty acids, and sterols as the main plant constituents [5]. It sometimes acts as a cardiac stimulant and lowers cholesterol levels [6]. Amla fruits are a wonderful tonic for strengthening and nourishing the lungs. Fruits with seeds are used for asthma, bronchitis, and biliousness. Furthermore, fruit is a gentle laxative, anti-oxidant, anti-aging, and anti-tumor. The therapeutic effects of *P. emblica*, which include antioxidant, anti-inflammatory, anti-hyperlipidemic, anti-diabetic, and neuroprotective activity, have been investigated as well [7–12]. The aqueous extract of *P. emblica* inhibited the growth of variant cancer cell lines, A549 (lung), HepG2 (liver), HeLa (cervical), MDA-MB-231 (breast), SK-OV3 (ovarian), and SW620 (colorectal) [13–16].

Due to its medicinal value, the phenolics, flavonoids, vitamin C, vitamin E, and some mineral contents of leaves, fruits, and stem branches of *P. emblica* L. cultivated in Egypt are evaluated in this research. Chromatographic isolation and spectroscopic identification of various Amla leaves and fruit constituents are also reported. In addition, the antioxidant and antimicrobial properties of solvent extracts and fractions of various organs of *P. emblica* L. were determined.

Today, one of the proposed preventive effects associated with the bioactive compounds in Amla is the reduction of neurological abnormalities, particularly the biochemical changes seen in carriers of Alzheimer's disease [9]. Therefore, the possible exploitation of the isolated compounds as anti-Alzheimer's disease operating by inhibition of acetylcholinesterase was evaluated by computational molecular docking.

2. Materials and Methods

2.1. General Experimental Procedures

UV spectra were recorded using Shimadzu UV-Viz, 1601 PC ultraviolet spectrometer (Shimadzu, Kyoto, Japan). For vitamin C determination, a Jupiter C-18 HPLC column (Phenomenex security system), a Jasco 870-UV detector (Jasco spectroscopic, Tokyo, Japan), a guard cell (Model 5020 operating at ± 200 mV), a Waters 6000 A eluent pump (Waters, Milford, OH, USA), a Waters Wisp 710 B refrigerated autosampler coupled to the eluent pump, a reaction coil for mixing Dionex RP-1 pump with mobile phase, an ultracentrifuge, and a 0.45 μm membrane filter were used. For vitamin E determination, analytical Nova Pak C-18 HPLC columns containing C-18 pellicular packing material (degrade themselves 30–40 μm), an alliance separation module (model 2690, Waters), and a Waters 996 Photodiode array detector (PDA), solvent delivery pump (515; Waters, Milford, OH, USA) were used. For quantitative determination of minerals, a Perkin-Elmer, Optima 2000 DV ICP-MS

system, Australia, was used for the simultaneous multi-element detection of minerals, and a centrifuge was used to separate undissolved parts of the plant samples. MLTW 54 (Germany), a microwave oven equipped with polytetrafluoroethylene (PTFE) vessels, Bergh of Speed wave MWS, Germany, was used for sample digestion.

^1H and ^{13}C NMR spectra as well as 2D spectra were recorded on NMR Varian Inova AS 600 (Varian) operating at 600 MHz for ^1H and 151 MHz for ^{13}C and NMR Bruker operating at 400 MHz for ^1H and 100 MHz for ^{13}C using CDCl_3 , CD_3OD , $\text{DMSO}-d_6$ as solvents and the solvent peaks as internal references. Chemical shifts were recorded in ppm on δ scale while the coupling constant (J) values were estimated in Hertz (Hz). Electrospray ionization mass (ESIMS) data were acquired on an API-4000 instrument (AB Sciex, Framingham, MA, USA) using $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ (1:1, v/v) solvent. Electron impact (EI)MS was acquired on a JEOL mass spectrometer (70 eV). MCI-gel CHP-20P (Mitsubishi Chemical, Tokyo, Japan) and Sephadex LH-20 (GE Healthcare Bio-Science AB, Uppsala, Sweden) were used for column chromatography. RP-HPLC analysis was performed at 40 °C on a YMC-Pack ODS-A A-303 (YMC, Kyoto, Japan) column (4.6 i.d. \times 250 mm), using the solvent gradient indicated in the extraction isolation below. Preparative RP-HPLC was performed at 40 °C on a YMC-Pack ODS-A A-324 column (10 i.d. \times 300 mm) using the solvent systems as in the extraction isolation section below. TLC was performed on pre-coated silica gel 60 GF254 TLC plates (Fluka, Neu-Ulm, Germany) with visualization by spraying with *p*-Anisaldehyde-Sulphuric acid spray reagent. Preparative HPLC was performed on YMC-Pack ODS-A A-324 column (10 i.d. \times 300 mm) (YMC, Kyoto, Japan). Antimicrobial screening was performed on Trypticase soy agar medium (Oxoid, Hampshire, UK) composed of casein hydrolysate (17 g/L, Soya peptone (3 g/L), sodium chloride (5 g/L), potassium phosphate (2.5 g/L), glucose (2.5 g/L), and agar (17g/L).

2.2. Plant Material

Samples of *Phyllanthus emblica* L. used in this study were collected during the fruiting stage of plants growing in El Qanater gardens, Qaliubia Governorate, Egypt (usually in October and September of these years), and identified by Dr. Abd El Halim Mohamed Senior plant taxonomist, Flora and Phytotaxonomy Department, Agricultural Research Center, Dokki, Giza, and by Mrs. Therese Labib, Head Specialist for Plant Identification Unit, El-Orman Garden, Cairo, Egypt. A voucher specimen (No. BUPD-38) was deposited in the Herbarium of Pharmacognosy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.

2.3. Extraction and Isolation

The air-dried powdered leaves (1 kg) of *Phyllanthus emblica* L. were extracted with $\text{EtOH}/\text{H}_2\text{O}$ (8/2, v/v , 4 L \times 4) by maceration. The solvent was evaporated under reduced pressure at 40 °C to yield 120 g extract. The total EtOH extract was suspended in distilled H_2O (0.5 L) and partitioned in solvents of increasing polarities, including petroleum ether (1 L \times 4), DCM (1 L \times 4), EtOAc (1 L \times 4) and *n*-BuOH saturated with H_2O (1 L \times 4). The obtained fractions were distilled off in a rotary evaporator under reduced pressure and afforded the corresponding dry residues (12, 0.75, 32, and 62 g, respectively). The ethyl acetate fraction (10 g) was subjected to Sephadex LH-20 (GE Healthcare Biosciences, Uppsala, Sweden) (30 g, 1 \times 30 cm) chromatography and eluted with a gradient of $\text{H}_2\text{O}/\text{MeOH}$. Eluates were collected as 25 mL/fraction, and similar fractions were pooled together. The H_2O eluates yielded gallic acid (1, 300 mg) upon crystallization from MeOH . The eluate with $\text{H}_2\text{O}/\text{MeOH}$ (8:2, v/v) was subjected to RP silica gel column (30 \times 1.5 cm, i.d.) eluted with $\text{H}_2\text{O}/\text{MeOH}$ gradient containing 0.1% formic acid in 5% increments. The $\text{H}_2\text{O}/\text{MeOH}$ (60/40, v/v) eluate (100 mg) was subjected to Sephadex LH-20 (30 g, 1 \times 30 cm) using $\text{H}_2\text{O}/\text{MeOH}$ (20/80, v/v) as a mobile phase to obtain naringenin 7-*O*-(6''-*O*-galloyl)- β -D-glucopyranoside (2, 8 mg).

A part (10 g) of the *n*-BuOH fraction of the fruit extract, obtained by similar procedures of the leaves, was dissolved in 100 mL distilled water, then centrifuged. The water-soluble

materials were then dried under reduced pressure at 40 °C. A total of 1.2 g of the water-soluble dry residue (6 g) was submitted to an MCI gel CHP-20P column (1.1 i.d. × 37 cm) and eluted with H₂O, H₂O/MeOH (1/9, 1.5/8.5, 2/8, 3/7, 4/6, and 1/1), and MeOH. Eluates were collected in test tubes by a fraction collector adjusted at 700 drops/fraction. Similar fractions, as monitored by RP-HPLC, were grouped together. The H₂O eluate afforded a MeOH-insoluble residue, which was purified by repeated washing with MeOH and yielded 3,3'-di-*O*-methyl ellagic acid-4'-*O*-β-D-glucopyranoside (**3**, 3 mg). The early eluate with 10% aq. MeOH (36 mg) was subjected to preparative RP-HPLC purification with [H₂O/CH₃CN (9.3/0.7, *v/v*) + 1% CH₃COOH] furnished pure 1-*O*-galloylglycerol (**4**, 4.7 mg). The early eluate with 20% aq. MeOH afforded pure 1,6-digalloyl-β-D-glucose (**5**, 4.8 mg), the next eluate with H₂O/MeOH (8:2, *v/v*) afforded the tannin-related phenolic flavogallonic acid bislactone [**6**, 3.2 mg], whereas the late eluate (13 mg) afforded corilagin (**7**, 5.4 mg) upon preparative HPLC purification with [H₂O/CH₃CN (8.5/1.5, *v/v*) + 1% CH₃COOH]. The fractions eluted with H₂O/MeOH (7:3, *v/v*) were also distinguished as early eluted fractions (16 mg) and middle eluted fractions (11 mg), and late eluted fractions (5 mg). Preparative HPLC purification with [H₂O/CH₃CN (8/2, *v/v*) + 1% CH₃COOH] of the early and middle eluted fractions separately furnished pure ethyl gallate (**8**, 5.4 mg) and [3,4,8,9,10-pentahydroxydibenzo [b,d] pyran-6-one (uroolithin M5; **9**, 1.3 mg) from the respective fractions. Preparative HPLC purification with [H₂O/CH₃CN (7.5/2.5, *v/v*) + 1% CH₃COOH] of the late eluate with the H₂O/MeOH (6:4, *v/v*) furnished the pure (*E*)-*p*-coumaroyl-1-*O*-β-D-glucopyranoside (**10**, 1.6 mg). The H₂O/MeOH (4/6, *v/v*) eluate was rechromatographed over Sephadex LH-20 (10 × 0.5 cm, i.d.) with MeOH to afford 1,2,4,6-tetra-*O*-galloyl-β-D-glucopyranoside (**11**, 30 mg).

2.4. Spectroscopic Data of the Isolated Compounds

Gallic acid (**1**): white powder; its ¹H NMR (DMSO-*d*₆, 400 MHz) and ¹³C NMR data (DMSO-*d*₆, 100 MHz) are listed in Table 1.

Table 1. NMR data of compound **1** in comparison with the literature data [17].

Position	Compound 1		Gallic Acid (in DMSO- <i>d</i> ₆) [17]	
	δ _H ppm	δ _C ppm	δ _H ppm	δ _C ppm
1	–	121.2	–	120.9
2	6.91, s	109.2	6.91, s	109.2
3	–	145.8	–	145.9
4	–	138.4	–	138.4
5	–	145.8	–	145.8
6	6.91, s	109.2	6.91, s	109.2
7	–	168.2	–	167.9

Prunin 6''-*O*-gallate; Naringenin 7-*O*-(6''-*O*-galloyl)-β-D-glucopyranoside (**2**): yellow amorphous powder; its ¹H NMR (CD₃OD, 400 MHz) and ¹³C NMR data (CD₃OD, 100 MHz) are listed in Table 2.

Table 2. NMR data of compound **2** in comparison with the literature data [18].

Position	Compound 2		Prunin 6''- <i>O</i> -Gallate in (CD ₃) ₂ CO [18]
	δ _H ppm (H, mult., <i>J</i> in Hz)	δ _C ^a ppm	δ _H ppm (H, mult., <i>J</i> in Hz)
2	5.38 (1H, dd, <i>J</i> = 12.6, 3.2)	78.8	5.41 (1H, td, <i>J</i> = 12)
3	2.77 (H-3 <i>eq.</i> dd, <i>J</i> = 17.1, 3.2) 3.16 (H-3 <i>ax.</i> dd, <i>J</i> = 17.1, 12.6)	42.4	3.0 (2H, m)
4	–	198.0	–
5	–	163.1	–
6	6.18 (H, d, <i>J</i> = 2.5)	96.7	6.23 (H, br s)
7	–	165.1	–

Table 2. Cont.

Compound 2		Prunin 6''-O-Gallate in (CD ₃) ₂ CO [18]	
Position	δ_{H} ppm (H, mult., <i>J</i> in Hz)	δ_{C} ^a ppm	δ_{H} ppm (H, mult., <i>J</i> in Hz)
8	6.18 (H, d, <i>J</i> = 2.5)	95.4	6.23 (H, br s)
9	–	163.1	–
10	–	103.4	–
1'	–	129.4	–
2', 6'	7.28 (2H, d, <i>J</i> = 8.5)	127.9	7.35 (2H, d, <i>J</i> = 9)
3', 5'	6.81 (2H, d, <i>J</i> = 8.5)	115.1	6.87 (2H, d, <i>J</i> = 9)
4'	–	157.2	–
1''	5.04 (1H, d, <i>J</i> = 7.2)	99.3	5.18 (1H, d, <i>J</i> = 7)
2''	3.79 (1H, m)	73.1	–
3''	–	76.1	–
4''	3.50 (3H, m)	70.5	3.3–4.1 (4H, m)
5''	–	74.1	–
6''	4.61 (1H, dd, <i>J</i> = 12.0, 2.2)	63.4	4.50 (2H, m)
	4.41 (1H, dd, <i>J</i> = 12.0, 5.9)		
1'''	–	119.7	–
2''', 6'''	7.06 (2H, s)	109.1	7.07 (2H, s)
3''', 5'''	–	145.0	–
4'''	–	138.6	–
7'''	–	167.2	–

^a The ¹³C NMR data of compound 2 are first-time reported in this research.

3,3'-di-O-methyl ellagic acid-4'-O-β-D-glucopyranoside (**3**): off-white amorphous powder; its ¹H NMR [DMSO-*d*₆/D₂O, 9/1, *v/v*, 600 MHz] and ¹³C NMR [DMSO-*d*₆/D₂O, 9/1, *v/v*, 151 MHz] data are listed in Table 3; its HSQC and HMBC spectra are composed in the Supplementary Materials; ESIMS *m/z* 491 [M – H][–] [19].

Table 3. NMR data of compound 3.

Position	δ_{H} ppm (H, mult., <i>J</i> in Hz)	δ_{C} ppm
1	–	111.1
2	–	140.9
3	–	140.1
4	–	151.5
5	7.54 (1H, s)	111.6
6	–	111.9
7	–	158.3
1'	–	114.1
2'	–	141.6
3'	–	141.8
4'	–	152.8
5'	7.81 (1H, s)	111.9
6'	–	112.7
7'	–	158.3
3-O-Me	4.05	61.0
3'-O-Me	4.09	61.6
1''	5.14 (1H, d, <i>J</i> = 7.8 Hz, H-1'')	101.3
2''	3.35 (2H, overlapped with solvent signal)	73.3
3''	–	76.4
4''	3.27 (1H, t, <i>J</i> = 9)	69.5
5''	3.43 (1H, ddd, <i>J</i> = 2.4, 5.4, 12)	77.2
	3.70 (1H, d, <i>J</i> = 12.6),	
6''	3.52 (1H, dd, <i>J</i> = 5.4, 12.6)	60.5

1-*O*-galloylglycerol (**4**): colorless prisms (H₂O); ¹H NMR [acetone-*d*₆/D₂O, 9/1, *v/v*, 600 MHz] and ¹³C NMR [acetone-*d*₆/D₂O, 9/1, *v/v*, 150 MHz] are listed in Table 4; its ¹H-¹H COSY, HSQC, and HMBC spectra are composed in the Supplementary Materials [20].

Table 4. NMR data of compound 4.

Position	δ_{H} ppm (H, mult., <i>J</i> in Hz)	δ_{C} ppm
1	4.24 (1H, dd, <i>J</i> = 11.4, 4.3) 4.15 (1H, d, <i>J</i> = 11.4)	66.2
2	3.92 (1H, m, H-2)	70.3
3	3.58 (2H, m, H-3)	63.2
1'	–	120.8
2'	–	109.7
3'	–	145.6
4'	–	138.8
5'	7.81 (1H, s)	145.6
6'	–	109.7
7'	–	167.5

1,6-digalloyl- β -D-glucose (**5**): off-white amorphous powder; ¹H NMR [CD₃OD/D₂O, 9/1, *v/v*, 600 MHz] are listed in Table 5; its ¹H-¹H COSY spectrum is composed in the Supplementary Materials.

Table 5. ¹H NMR data of compound 5 in comparison with the literature data [21].

Position	Compound 5	1,6-Digalloyl- β -D-glucose (CD ₃ OD) [21]
	δ_{H} ppm (H, mult., <i>J</i> in Hz)	δ_{H} ppm (H, mult., <i>J</i> in Hz)
Glucose 1	5.67 (1H, d, <i>J</i> = 7.8)	5.73 (1H, d, <i>J</i> = 7.8)
2		
3		
4	3.55–3.75 (4H, m)	3.55–3.75 (4H, m)
5		
6	4.39 (1H, dd, <i>J</i> = 12.0, 5.4) 4.55 (1H, dd, <i>J</i> = 12.0, 2.0)	4.44 (1H, dd, <i>J</i> = 12.0, 5.4) 4.59 (1H, dd, <i>J</i> = 12.0, 1.8)
Galloyl [(H-2/H-6) × 2]	7.08, 7.13 (each 2H, s)	7.12, 7.17 (each 2H, s)

Flavogallonic acid bislactone (**6**): off-white amorphous powder; ¹H NMR [acetone-*d*₆/D₂O, 9/1, *v/v*, 600 MHz] and ¹³C NMR [acetone-*d*₆/D₂O, 9/1, *v/v*, 151 MHz] are listed in Table 6; its HSQC and HMBC spectra are composed in the Supplementary Materials.

Table 6. NMR data of compound 6 in comparison with the literature data [22].

Position	Compound 6		Flavogallonic Acid Bislactone in CD ₃ OD [22]	
	δ_{H} ppm (H, mult., <i>J</i> in Hz)	δ_{C} (ppm)	δ_{H} ppm (H, mult., <i>J</i> in Hz)	δ_{C} ppm
1	–	108.8 ^a	–	108.1
2	–	136.3	–	135.7
3	–	137.3	–	136.3
4	–	137.8	–	136.5
5	–	111.1	–	112.8
6	7.29 (1H, s)	110.9	7.26 (1H, s)	110.1
7	–	160.5	–	160.4

Table 6. Cont.

Position	Compound 6		Flavogallonic Acid Bislactone in CD ₃ OD [22]	
	δ_{H} ppm (H, mult., <i>J</i> in Hz)	δ_{C} (ppm)	δ_{H} ppm (H, mult., <i>J</i> in Hz)	δ_{C} ppm
1'		109.0 ^a		108.1
2'	–	138.9	–	137.8
3'	–	139.8	–	139.2
4'	–	144.1	–	143.2
5'	–	118.1	–	117.5
6'	–	113.9	–	114.4
7'	–	158.5	–	158.9
1''	–	125.8	–	124.9
2''	–	121.3	–	120.2
3''	–	144.7	–	144.1
4''	–	146.6	–	145.9
5''	–	148.4	–	147.8
6''	7.57 (1H, s)	113.2	7.50 (1H, s)	113.3
7''	–	168.2	–	168.9

^a exchangeable.

Corilagin (7): yellow amorphous powder; ¹H NMR [CD₃OD + D₂O, 9/1, *v/v*, 600 MHz] and ¹³C NMR [CD₃OD/D₂O, 9/1, *v/v*, 151 MHz] are listed in Table 7; its ¹H-¹H COSY, HSQC, and HMBC spectra are composed in the Supplementary Materials [23,24].

Table 7. NMR data of compound 7.

Position	δ_{H} ppm (H, mult., <i>J</i> in Hz)	δ_{C} ppm
Glucose 1	6.34 (1H, d, <i>J</i> = 2)	95.84
2	4.00 (1H, brs)	70.07
3	4.81 (1H, brs)	72.31
4	4.45 (1H, brs)	63.22
5	4.52 (1H, br t, <i>J</i> = 8)	76.89
6	4.15 (1H, dd, <i>J</i> = 11, 8) 4.92 (1H, t, <i>J</i> = 11)	65.76
Galloyl 1	–	121.3
2/6	7.05 (2H, s)	111.8
3/5	–	147.1
4	–	141.2
7	–	167.6
HHDP 1,1'	–	117.4, 118.0
2,2'	–	126.2, 126.3
3,3'	6.69, 6.66 (each 1H, s)	109.1, 111.1
4,4'	–	146.4, 146.8
5,5'	–	138.7, 139.0
6,6'	–	146.0, 146.1
7,7'	–	169.4, 170.9

Ethyl gallate (8): off-white crystals (MeOH); ¹H NMR [acetone-*d*₆/D₂O, 9/1, *v/v*, 600 MHz] and ¹³C NMR (acetone-*d*₆/D₂O, 9/1, *v/v*, 151 MHz) are listed in Table 8; its HSQC and HMBC spectra are composed in the Supplementary Materials [25].

Table 8. MR data of compound 8.

Position	δ_{H} ppm (H, mult., <i>J</i> in Hz)	δ_{C} ppm
Galloyl 1	–	121.0
2/6	7.06 (2H, s)	109.5
3/5	–	145.9
4	–	138.7
7	–	167.2
Ethyl CH ₂	4.21 (2H, q, <i>J</i> = 7.1)	60.9
Ethyl CH ₃	1.27 (3H, t, <i>J</i> = 7.1)	14.5

3,4,8,9,10-pentahydroxydibenzo [b,d] pyran-6-one (uroolithin M5, **9**): colorless needles; ^1H NMR [acetone- d_6 /D $_2$ O, 9/1, v/v , 600 MHz] and ^{13}C NMR [acetone- d_6 /D $_2$ O, 9/1, v/v , 151 MHz] are listed in Table 9 [26].

Table 9. NMR data of compound **9**.

Position	Compound 9		Urolithin M5 in CD $_3$ OD [26]	
	δ_{H} ppm (H, mult., J in Hz)	δ_{C} ppm	δ_{H} ppm (H, mult., J in Hz)	δ_{C} ppm
1	8.4 (1H, d, $J = 9$)	118.4	8.44 (1H, d, $J = 9$)	119.2
2	6.8 (1H, d, $J = 9$)	112.0	6.77 (1H, d, $J = 9$)	112.5
3	–	145.9	–	144.0
4	–	133.5	–	133.3
4a	–	140.3	–	140.9
5	–	–	–	–
6	–	162.1	–	163.9
6a	–	112.0	–	112.0
7	7.40 (1H, s)	107.9	7.37 (1H, s)	108.2
8	–	146.0	–	146.4
9	–	147.8	–	146.7
10	–	143.3	–	141.9
10a	–	112.2	–	112.8

(E)-*p*-coumaroyl-1-*O*- β -D-glucopyranoside (**10**): off-white amorphous powder; ^1H NMR [acetone- d_6 /D $_2$ O, 9/1, v/v , 600 MHz] and ^{13}C NMR [acetone- d_6 /D $_2$ O, 9/1, v/v , 151 MHz] are listed in Table 10; its ^1H - ^1H COSY, HSQC, and HMBC spectra are composed in the Supplementary Materials [27].

Table 10. NMR data of compound **10**.

Position	δ_{H} ppm (H, mult., J in Hz)	δ_{C} ppm
1	–	118.1
2/6	7.42 (2H, dd, $J = 8.4, 9.0$)	129.7
3/5	7.68 (2H, dd, $J = 8.4, 9.0$)	129.1
4	–	146.8
7	7.76 (1H, d, $J = 16$)	135.0
8	6.56 (1H, d, $J = 16$)	131.4
9	7.40 (1H, s)	166.2
Glucose 1	5.57 (1H, d, $J = 8.1$)	95.4
2	–	77.3
3	–	73.4
4	3.39–3.53 (4H, m)	70.6
5	–	78.2
6	3.80 (1H, dd, $J = 12.1, 2.4$)	–
	3.65 (1H, dd, $J = 12.1, 5.4$)	62.0

1,2,4,6-tetra-*O*-galloyl- β -D-glucopyranoside (**11**): ^1H NMR [CD $_3$ OD, 400 MHz] data are listed in Table 11; its ^{13}C NMR spectrum is composed in the Supplementary Materials.

Table 11. ^1H NMR data of compound **11** in comparison with 2.5.1 the literature data [28].

Position	Compound 11	1,2,4,6-Tetra- <i>O</i> -galloyl- β -D-glucopyranoside in CD $_3$ OD [28]
	δ_{H} ppm (H, mult., J in Hz)	δ_{H} ppm (H, mult., J in Hz)
Galloys H-2/H-6	7.12, 7.11, 7.07, 7.05 (each 2H, s)	7.12, 7.11, 7.07, 7.05 (each 2H, s)
Glucose 1	6.07 (1H, d, $J = 8.4$)	6.07 (1H, d, $J = 8.4$)
2	5.36 (1H, dd, $J = 8.4, 9.6$)	5.37 (1H, dd, $J = 8.4, 9.6$)
3	4.18 (1H, t, $J = 9.6$)	4.16 (1H, t, $J = 9.6$)
4	5.39 (1H, t, $J = 9.6$)	5.38 (1H, t, $J = 9.6$)
5	4.22 (1H, m)	4.19 (1H, m)
6	4.48 (1H, dd, $J = 1.8, 12.3$)	4.49 (1H, dd, $J = 1.8, 12.3$)
	4.31 (1H, dd, $J = 4.2, 12.6$)	4.29 (1H, dd, $J = 4.2, 12.6$)

2.5. Metabolite Quantification

2.5.1. Total Phenolic Content

The Folin-Ciocalteu method was used to calculate the extract's total phenolic content [29]. Briefly, an aliquot, 1 mL of each of the gallic acid solutions, and the tested extracts were introduced into a volumetric flask (25 mL) containing distilled water (9 mL); 1 mL of Folin-Ciocalteu reagent was added 5 min later 10 mL of Na₂CO₃ (7%) was added, the volume was adjusted with distilled water to the mark. The solution was mixed carefully and left for 90 min, at room temperature. A blank experiment was processed in the same way using 1 mL of distilled water. Absorbance using a UV-VIS spectrophotometer was measured at 750 nm. The standard gallic acid calibration curve (regression equation: $y = 0.0334x + 0.0993$, $R^2 = 0.9971$) was used to obtain the total phenolics. The total phenolic content in each sample was expressed as mg of gallic acid equivalent (GAE)/1 g dry weight of the extract.

2.5.2. Total Flavonoid Content

The aluminium chloride colorimetric technique was used to determine the total flavonoid content of crude extract [30]. One ml of each of the tested samples and standard solutions were separately introduced into 10 mL volumetric flasks containing 4 mL distilled water, followed by the addition of 0.3 mL NaNO₂ (5%). After 5 min of incubation, 0.3 mL of 10% AlCl₃ solution was added, and the combination was left to stand for 6 min. After the addition of 2 mL of a 1 M NaOH solution, the final volume of the combination was then raised to 10 mL using double-distilled water. After 15 min of standing time, the mixture was tested for absorbance at 510 nm against a blank solution prepared with 1 mL of distilled water. The standard quercetin calibration curve (regression equation: $y = 0.002x + 0.0255$, $R^2 = 0.9903$) was used to obtain the total flavonoids, which was then reported as mg quercetin equivalent per g dry weight of the extract.

2.5.3. Determination of Tannins Content

Dried powdered plant samples (each 1 g) were thoroughly extracted with 100 mL of distilled water for one h using an ultrasonic bath at room temperature. The extract was filtered in a 100 mL volumetric flask, and the filtrate was adjusted to volume with distilled water. An aliquot (5 mL) of the filtrate was transferred to the test tube and treated with 2 mL of 0.1 M FeCl₃ solution (dissolved in 0.1 N HCl containing 0.008 M potassium ferrocyanide). The absorbance was measured within 10 min, at 550 nm against a blank solution, prepared with distilled water. The standard calibration curve of gallic acid with ferric chloride (regression equation: $y = 0.0042x + 1.1494$, $R^2 = 0.9876$) was used to obtain the total tannins. The tannin content was calculated in terms of gallic acid equivalent (GAE) mg/1 g dry weight [31].

2.6. Nutritional Values

2.6.1. Vitamin C Content

Vitamin C was determined based on Kall and Andersen 1999 [32]. Fresh leaves and fruits (25 g each) were mixed with 100 mL extraction buffer composed of 1% metaphosphoric acid with 0.5% oxalic acid. The mix was transferred into a blender with a further 70 mL of the extraction buffer. Oxygen was evacuated by passing a stream of CO₂ through the suspension for 3 min. After blending for 5 min, the resulting solutions were quantitatively completed into 250 mL with the extraction buffer. Aliquots were centrifuged for 10 min at 9×10^3 rpm at 4 °C. The supernatant was filtered (0.45- μ m filter) before the HPLC analyses according to the conditions shown in (Table 1).

2.6.2. Vitamin E Content

Vitamin E was determined based on the reported method [33]. The ground leaves and fruits (2 g each) were added separately in a 15 mL ethanol containing vitamin C (20%, v/v) in a saponification vessel and vortex for 30 s. After sonication for 15 min, 5 mL of

KOH (33.6 g/L) was added, and the vessel was flushed with Argon gas for 1 min. An air condenser was connected, and the contents were digested at 70 °C for 15 min in a shaking water bath. The samples were cooled for 5 min in an ice bath, and then 20 mL of NaCl (20 g/L) was added and vortexed for 30 s. The unsaponifiable fractions were extracted with diethyl ether (20 mL). The ether was evaporated and the unsaponifiable fractions were extracted three times with 20 mL *n*-heptane containing 0.1 g/L of butylated hydroxyl toluene (BHT). The extracts were collected, then centrifuged and diluted to a final volume of 50 mL and filtered through a 0.2 µm filter prior to HPLC analyses according to the conditions in Table 12. Experiments were repeated three times. The compound peaks were identified based on the retention times of the external standards vitamins C and E. The concentrations were calculated from peak areas determined by linear regression.

Table 12. Conditions of HPLC analysis of vitamin C and E.

Condition	Vitamin C	Vitamin E
Column	RP C-18 Jupiter ODS-2 (5 µm)	RP C-18 Nova Pak ODS-2 (4 µm)
Dimensions	250 × 4.6 mm i.d.	300 × 3.9 mm i.d.
Mobile phase	2.3 mM Na ₂ EDTA in 66 mM phosphate-20 mM acetate buffer (pH = 4.50)	Isocratic (isopropanol: heptane, 1: 99, v/v)
Flow rate	1.2 mL/min	2 mL/min
Detector	UV spectrophotometer	Photodiode array detector (PDA)
Detector UV wavelength	247 nm	195–330 nm
Injection volume	20 µL	10 µL
Column temperature	20 °C	40 °C
Run time	14 min	13 min
Photodiode array (PDA) measurement frequency	----	1 spectrum/s
PDA spectral resolution	----	1.2 nm

2.6.3. Mineral Content

The leaves, stem branches, and fruits (200 mg oven dried of each) were separately washed thoroughly with tap water followed by distilled water, dried at 105 °C, ground using a mortar, and stored in plastic bags until analysis. The dried powdered leaves, stem branches, and fruits (200 mg of each) were added to a polytetrafluoroethylene (PTFE) digestion vessel, 5 mL conc. HNO₃ and 3 mL conc. H₂O₂ were added to the vessel and left for approximately 20 min before the vessel was closed. Sample decomposition was carried out in a microwave digestion system. A top-step program (Table 13) was applied to the samples. The undissolved parts were separated with centrifugation at 4000 rpm for 10 min. The extracts were transferred into a volumetric flask and made up to 25 mL with double distilled water. Blank experiments (n = 3) were carried out. Through analysis of the certified reference material (GBW07605 tea sample), the method's accuracy was examined [34].

Table 13. Operating conditions of inductively coupled plasma mass spectrometry (ICP-MS).

Nebulizer	Babington Type
Spray chamber	Quartz, double pass
Radiofrequency (RF) generator Frequency	10 MHz, power output:1220W
Air flow rate (L/min)	20
Auxiliary gas flow rate (L/min)	0.9
Nebulizer gas flow rate (L/min)	1–1.2
Sample uptake (L/min)	400
Number of replicates	3
Integration time	0.1
Internal standards	Bi, Be, Rh, Sc
Isotopes	⁵⁷ Fe, ⁶⁶ Zn, ³⁹ K, ²² Na
	UV wavelengths of the determined minerals.
Mineral	Wavelength
Sodium	589.592 nm
Potassium	766.490 nm
Zinc	206.200 nm
Iron	238.204 nm

2.7. Biological Investigations

2.7.1. Antioxidant Assay

Stock solutions (1 mg/mL) prepared in absolute ethanol of the leaves, stem branches and fruit extracts as well as gallic acid was diluted to final concentrations of 250, 125, 50, 25, and 5 µg/mL in ethanol. DPPH (1,1-Diphenyl-2-picryl-hydrazyl) was used as a free radical scavenger in the antioxidant activity. Ascorbic acid (E-Merck, Germany) was used as a reference drug, while absolute ethanol was used as a control. The ability of the extracts to scavenge DPPH free radicals was assessed using a published method [35]. One ml of 0.3 mM DPPH ethanol solution was added to 2.5 mL of sample solutions of different concentrations and allowed to react at room temperature. After 30 min, the absorbance values were measured at 518 nm and converted into percentage inhibition according to the following formula:

$$\text{Inhibition (\%)} = [(A_{\text{control}} - A_{\text{sample}})] / (A_{\text{control}}) \times 100$$

2.7.2. Antimicrobial Assay

The total ethanolic extract as well as the petroleum ether, methylene chloride, ethyl acetate, and butanol fractions of both leaf and fruit were investigated for their antimicrobial effect against certain Gram-positive bacteria, *Bacillus subtilis* (ATCC-6051), *Staphylococcus aureus* (ATCC-12600), and *Streptococcus faecalis* (ATCC-19433), Gram-negative bacteria, *Escherichia coli* (ATCC-11775), *Pseudomonas aeruginosa* (ATCC-10145), and *Neisseria gonorrhoeae* (ATCC-19424), and fungi, *Candida albicans* (ATCC-26555) and *Aspergillus flavus* (ATCC 15517). The micro-organisms used were obtained from Micro Analytical Center, Cairo University. The agar diffusion method was applied using a Trypticase soy agar (Difco) medium inoculated with the bacterial or fungal suspension of the test organisms [36]. The tested extracts of the plant were dissolved in dimethyl sulfoxide (DMSO) in the concentration of 200 mg/mL, and 50 µL was aseptically transferred into sterile discs (10 mg/disc) of Whatman filter paper (5 mm in diameter). The plates were incubated at 37 °C for 24 h in the case of bacteria and at 25 °C for 48 h in the case of fungi. After incubation, the inhibition zones were recorded in mm. Three replicates were carried out and the average inhibition zones were determined.

2.8. Investigations of Anti-Acetylcholinesterase by Molecular Docking

Molecular docking calculations of the target compounds were performed using the AutoDock Vina program [37]. The crystal structure of the protein was retrieved from the Protein Data Bank (PDB ID: 4EY7). The water molecules in the proteins were removed and polar hydrogen was added to make these receptors prepared for docking [38–40]. In the 40 Å × 40 Å × 40 Å grid sizes, active protein regions were established for the process. The structure of the selected proteins was parameterized using AutoDock Tools [41]. Furthermore, the molecular docking protocol was validated as reported in the literature [42–44]. Compounds used in this study were drawn using Avogadro software (v1.2.0). Affinity scores (in kcal/mol) provided by AutoDock Vina for all compounds were obtained and ranked based on the free energy binding theory (greater negative value means greater binding affinity) [45]. The resulting structures and the binding docking poses were graphically inspected to check the interactions using DS Visualizer 2.5 (<http://3dsbiovia.com/products/>, accessed on 19 July 2023).

3. Results

3.1. Identification of Isolated Compounds

Even though isolating compounds from a natural source is a difficult and time-consuming operation, it is essential to comprehend the phytochemical makeup of the sample and precisely determine the biological effects of the compounds. In this research, we purified eleven phytomolecules from aqueous methanol extracts of leaves and fruits of *P. emblica*. The structures of the isolated compounds (1–11, Figure 1) were identified

from the spectroscopic data [see the listed data in the experimental section (Tables 1–11) and the 1D and 2D NMR spectra composed in the Supplementary Materials file associated with this article] and the comparison with those obtained from the literature. The isolated compounds are categorized as flavonoids, naringenin 7-*O*-(6''-*O*-galloyl)- β -D-glucopyranoside (2), simple tannin-like phenolics, gallic acid (1), 3,3'-di-*O*-methyl ellagic acid-4'-*O*- β -D-glucopyranoside (3), 1-*O*-galloyl glycerol (4), flavogallonic acid bislactone (6), ethyl gallate (8), urolithin M5 (9), (E)-*p*-coumaroyl-1-*O*- β -D-glucopyranoside (10), and tannins, 1,6-di-*O*-galloyl- β -D-glucopyranoside (5), corilagin (7), and 1,2,4,6-tetra-*O*-galloyl- β -D-glucopyranoside (11) [17–27]. According to our knowledge, among these isolates, compounds 3 and 10 are first isolated from the plant, and the ^{13}C NMR data of compound 2 are reported for the first time in this research.




Figure 1. Structures of isolated compounds 1–11 from *P. emblica*.

3.2. Total Phenolic, Flavonoid, and Tannin Contents

Results obtained from this quantitative study are recorded in (Table 14). It is obvious that the total phenolic contents were higher in fruits (29 mg GAE/g dry extract) and leaves (29 mg GAE/g dry extract) than stems (mg GAE/g dry weight). The fruits contain the highest quantity of flavonoids (24 mg QE/g dry extract) followed by leaves (13 mg QE/g dry extract) and stem branches (4.5 mg QE/g dry extract). The highest tannins content was present in the stem branches (4.2 mg/g dry weight) followed by leaves (2.48 mg/g dry weight) and fruits (2.2 mg/g dry weight).

Table 14. Total phenolic, flavonoid, and tannin contents in different organs of *Phyllanthus emblica* L.

Plant Organ	Total Phenolics (mg GAE/g Dry Extract)	Total Flavonoids (mg QE/g Dry Extract)	Total Tannins (mg GAE/g Dry Extract)
Leaves	29 ± 1	13 ± 0.2	2.5 ± 0.1
Fruits	29 ± 1	24 ± 0.4	2.2 ± 0.2
Stem branches	8 ± 1	4.5 ± 0.1	4.2 ± 0.1

3.3. The Nutritional Values

Nutritive value of the plant was determined via analysis of vitamins C and E and minerals contents. Analysis results (Table 15) revealed that the fruits contain a high content of vitamin C (282 mg/100 g of fresh fruits). Leaves contain considerable amounts of vitamin C and vitamin E (19, 10 mg/100 g fresh wt.) which make it a rich source for these vitamins. This encourages the use of fresh leaf extracts as a rich vitamin supplement.

Natural minerals content (Table 16) revealed the highest content of potassium is present in fruits (13,510 mg/kg dry weight) which is higher than banana content (3800 mg/kg) [46]. The highest content of sodium is in stem branches (807 mg/kg dry wt.). Leaves contain a high amount of iron (1039 mg/kg), which makes them a good iron supplement. Previous reports on *P. emblica* showed that sodium, potassium, and zinc contents are 4.2, 282, 1.8 mg/100 g fresh weight of fruits [2]. No previous reports dealt with the mineral content of leaves or stem branches.

Table 15. Vitamins C and E contents of the leaves and fruits of *P. emblica* L.

Vitamin	Content (mg/100 g Fresh Sample)			RAD for Adults (Amount/Day)
	Leaves	Fruits		
Vitamin C	19 ± 1	282 ± 6		60 mg
Vitamin E	10 ± 0.9	0.34 ± 0.001		13 mg

RAD: recommended dietary allowances [47].

Table 16. Amount of minerals detected in the leaves, stem branches, and fruits of *P. emblica*.

Mineral	Content (mg/kg Dry Weight)			RAD for Adults (Amount/Day)
	Leaves	Stem Branches	Fruits	
Zinc	17 ± 2	20 ± 1	4 ± 0.2	15 mg
Sodium	443 ± 64	807 ± 7	194 ± 4	23 mg
Potassium	10,725 ± 136	8665 ± 11	13,510 ± 11	90 mg
Iron	1039 ± 10	25 ± 4	NA	10 mg

NA: not analysed. RAD: recommended dietary allowances [47].

3.4. Biological Properties

3.4.1. The Antioxidant Activity

The antioxidant activity of the various extracts of *P. emblica* was tested by the DPPH• free radical scavenging method. The IC₅₀ values were compared with that of ascorbic acid. The results showed that the H₂O/ethanol (2/8, v/v) extract of the fruits exhibited antioxidant activity that was higher by 8% than the standard ascorbic acid, while the ethyl acetate fraction of the fruits was the most active fraction followed by that of the leaves

with IC_{50} values of 3.20 and 6.10 $\mu\text{g}/\text{mL}$, respectively (Figure 2). The ethyl acetate obvious antioxidant activity may be attributed to the accumulation of a large amount of the powerful antioxidant gallic acid [(1), IC_{50} 4.53] and the flavonoid (2) (see extraction and isolation section). Previous numerous in vitro studies, including those using the DPPH radical, the 2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS), nitric oxide radical, the ferric reducing antioxidant power (FRAP), and the LDL oxidation assay methods [8], support our antioxidant activity of *P. emblica* which is herein shown.




Figure 2. IC_{50} of DPPH• scavenging activity of different *P. emblica* extracts in comparison with isolated gallic acid and standard ascorbic acid. Error bars indicate standard errors of the means of triplicate experiments.

3.4.2. Antimicrobial Activity

The antimicrobial screening results (Table 17) revealed that leaf extracts showed the most powerful and broad-spectrum antimicrobial activity against all tested bacterial species. The total extract of leaves exhibited a wide inhibition zone against *B. subtilis*, *S. aureus*, and *P. aeruginosa*, which is ~75% of the inhibition zone of the tetracycline antibiotic. The EtOAc and BuOH subextracts also exhibited a comparable inhibition zone against the same bacterial species. None of the petroleum ether and the MeOH subextracts exhibited strong activity against the bacterial species. Fruit extracts showed moderate broad-spectrum activity against tested bacteria. Total ethanolic extracts of leaves and fruits, and ethyl acetate subextracts of leaves and butanol subextract of fruit, exhibit moderate activity against *Candida albicans*. None of the extracts exhibited activity against *Aspergillus flavus*.

3.5. Computational Investigation Antiacetylcholinesterase Properties of Isolated Compounds

In a recent study, a crude methyl extract of *P. emblica* fruit has been found strongly active in inhibiting acetylcholinesterase (AChE) and butyrylcholinesterase with IC_{50} of 53.88 $\mu\text{g}/\text{mL}$ and 65.12 $\mu\text{g}/\text{mL}$, respectively [48]. This suggests that *P. emblica* is a rich source of AChE and BuChE inhibitors. It would be a significant achievement if any compound obtained from *P. emblica* has the potential to be an effective treatment for Alzheimer's disease. In the current study, the molecular docking evaluation of the anticholinesterase action of the isolated molecules was attempted. The results of the molecular docking investigation (Table 18) revealed a high binding affinity (low docking score) and hence a possible acetylcholinesterase inhibitory effect of the compounds. The highest binding affinity was seen among the ligand prunin 6''-O-gallate (naringenin 7-O-(6''-O-galloyl)- β -D-glucopyranoside (2, -12.4 kcal/mol)]. The tannins 1,2,4,6-tetra-O-galloyl- β -D-glucopyranoside (11) and 1,6-di-O-galloyl- β -D-glucopyranoside (6) and corilagin (7) were the next in their binding affinities with docking scores of -11.1 , -10.7 , and -10.1 kcal/mol, respectively. Next, urolithin M5 (9) also exhibited a considerably high binding affinity (-9.8 kcal/mol)].

Table 17. Antimicrobial screening of different extracts of *P. emblica*.


Extract	Organ	Bacterial Species										Fungal Species					
		<i>B. subtilis</i>		<i>S. faecalis</i>		<i>S. aureus</i>		<i>E. coli</i>		<i>P. aeruginosa</i>		<i>N. gonorrhoeae</i>		<i>C. albicans</i>		<i>A. flavus</i>	
		I. Z. ^a	% ^b	I. Z. ^a	% ^b	I. Z. ^a	% ^b	I. Z. ^a	% ^b	I. Z. ^a	% ^b	I. Z. ^a	% ^b	I. Z. ^a	% ^b	I. Z. ^a	% ^b
Tot.	L	22 ± 2	73	16 ± 1	53	21 ± 1	75	19 ± 1	63	23 ± 2	74	18 ± 1	62	10 ± 1	50	0	0
EtOH	F	13 ± 1	43	14 ± 1	47	12 ± 1	43	15 ± 1	50	14 ± 1	45	12 ± 1	41	9 ± 1	45	0	0
Pet.	L	16 ± 2	53	15 ± 1	50	19 ± 2	68	15 ± 1	50	16 ± 1	52	16 ± 1	55	0	0	0	0
Ether	F	13 ± 1	43	13 ± 1	43	13 ± 1	46	13 ± 1	43	13 ± 1	42	12 ± 1	41	0	0	0	0
EtOAc	L	21 ± 1	70	19 ± 1	63	23 ± 1	82	17 ± 1	57	20 ± 2	65	23 ± 1	79	9 ± 0.2	45	0	0
	F	14 ± 1	47	13 ± 1	43	13 ± 1	46	13 ± 1	43	12 ± 1	39	12 ± 1	41	0	0	0	0
BuOH	L	18 ± 11	60	17 ± 1	57	23 ± 1	82	19 ± 1	63	20 ± 1	65	23 ± 1	79	0	0	0	0
	F	11 ± 1	37	12 ± 1	40	15 ± 1	54	11 ± 1	37	16 ± 1	52	13 ± 1	45	10 ± 1	50	0	0
MeOH	L	13 ± 1	43	12 ± 1	40	10 ± 1	36	12 ± 1	40	11 ± 1	35	10 ± 1	34	0	0	0	0
	F	1 ± 0.1	3	11 ± 1	37	12 ± 1	43	13 ± 1	43	11 ± 1	35	11 ± 1	38	0	0	0	0
Tetra.	L	30 ± 2	100	30 ± 1	100	28 ± 1	100	30 ± 1	100	31 ± 1	100	29 ± 2	100	--	--	--	--
Ampho.	F	--	--	--	--	--	--	--	--	--	--	--	--	20 ± 2	100	17	100

^a I. Z.: inhibition zone in mm. ^b: % of I. Z. of a sample relative to the corresponding antimicrobial standard, calculated from the equation (I.Z. of a sample/I.Z. of the corresponding standard antimicrobial × 100). Each value is the means of three readings ± SE. L.: leaf; F.: fruit; Tot. EtOH, 80 ethanol extract; Pet. ether: petroleum ether fraction; Met.ch.: methylene chloride fraction; Eth.ac.: ethyl acetate fraction; But.: butanol fraction; Tetra.: tetracycline; Ampho.: amphotericin B.

Table 18. Molecular docking results.

No	Compound	Binding Affinity (kcal/mol)
1	gallic acid	−6.6
2	Prunin 6''-O-gallate (Naringenin)	−12.4
3	7-O-(6''-O-galloyl)- β -D-glucopyranoside	−9.7
4	3,3'-di-O-methyl ellagic acid-4'-O- β -D-glucopyranoside	−7.8
5	1-O-Galloylglycerol	−10.7
6	1,6-di-O-galloyl- β -D-glucopyranoside	−9.3
7	flavogallonic acid bislactone	−10.1
8	Corilagin	−7.1
9	Ethyl gallate	−9.8
10	Urolithin M5	−9.2
11	(E)- <i>p</i> -coumaroyl-1-O- β -D-glucopyranoside	−11.1

The molecular docking studies of AChE to urolithin M5 (9) demonstrated that the molecule could establish H-bond with six various amino acids of the target receptor, including GLY120, TYR124, SER125, GLU202, TYR341, and GLY448. Moreover, one π - π stacked interaction was also found with TRP86 (Figure 3). On the other hand, as shown in Figure 4, the docking pose accomplished by naringenin 7-O-(6''-O-galloyl)- β -D-glucopyranoside involved six interactions with amino acid residues of GLY234, PRO235, GLY240, ARG247, GLU313, and GLN369 via hydrogen bond interaction. Additionally, three hydrophobic interactions were also observed with PRO235 and PRO410 (π -alkyl) and HIS405 (π - π T shaped), thus resulting in the binding affinity of −12.4 kcal/mol.

**Figure 3.** Shown interactions of urolithin M5 (9) in the active site of AChE (PBD ID: 4EY7).




Figure 4. Shown interactions of naringenin 7-*O*-(6''-*O*-galloyl)- β -D-glucopyranoside (2) in the active site of AChE (PBD ID: 4EY7).

4. Discussion

Numerous research publications have recently concentrated on the qualities of various foods (functional food or nutraceuticals) and established that functional foods and their ingredients have a part in lowering the risk of disease, treating it, and promoting human health. Consuming such nutraceuticals in moderation helps keep the redox state steady and reduce oxidative stress.

In our study, the leaves' and fruits' ethyl acetate and butanol fractions exhibited DPPH radical scavenging activity comparable to the known antioxidant gallic and ascorbic acids, respectively (Figure 2). This is consistent with the high levels of total phenolics, total flavonoids, and total tannins (Table 3) and overemphasized by the isolation of eleven compounds belonging to tannins [1,6-di-*O*-galloyl- β -D-glucopyranoside (5), corilagin (7), and 1,2,4,6-tetra-*O*-galloyl- β -D-glucopyranoside (11)], tannin-related phenolics [3,3'-di-*O*-methyl ellagic acid-4'-*O*- β -D-glucopyranoside (3), 1-*O*-galloyl glycerol (4), and flavogallonic acid bislactone (6), and urolithin M5 (9)], simple phenolics [gallic acid (1), ethyl gallate (8), and (*E*)-*p*-coumaroyl-1-*O*- β -D-glucopyranoside (10)], and a flavonoid [naringenin 7-*O*-(6''-*O*-galloyl)- β -D-glucopyranoside (2)].

According to previous research, one of the putative preventive benefits connected to the Amla bioactive compounds is the mitigation of neurological modifications, particularly the biochemical changes seen in carriers of Alzheimer's disease. A crude methyl extract of *P. emblica* fruit was found to be strongly active in inhibiting acetylcholinesterase (AChE) and

butyrylcholinesterase (BuChE) [48]. In another in vitro study, *P. emblica* fruit polyphenols exhibited strong antioxidant capacities in scavenging free radicals and anti-cholinesterase ability by inhibition of AChE and BuChE. This suggests that *P. emblica* is a rich source of phytochemicals with antioxidants and inhibitors of AChE and BuChE.

To discover further about the protective effects of Amla bioactive molecules against Alzheimer's disease, the acetylcholinesterase inhibitory effect of isolated compounds 1–11 was computationally investigated. Results of molecular docking (Table 18) revealed a high binding affinity (low docking score) and hence a possible high acetylcholinesterase inhibitory effect of the compounds. The highest binding affinity was seen among the ligand and prunin 6''-O-gallate (2, −12.4 kcal/mol), the tannins 1,2,4,6-tetra-O-galloyl-β-D-glucopyranoside (11, −11.1 kcal/mol), 1,6-di-O-galloyl-β-D-glucopyranoside (6, −10.7), corilagin (7, −10.1 kcal/mol), and urolithin M5 (9, −9.8 kcal/mol).

The acetylcholinesterase inhibitory effects of naringenin 7-O-(6''-O-galloyl)-β-D-glucopyranoside were not reported early; however, the aglycone part, naringenin, showed a diminishing effect on amnesia due to its inhibitory effect on acetylcholinesterase [49]. It also attenuated behavioral instabilities induced by social-conquer tension in mice via the inhibition of acetylcholinesterase activity, oxidative stress, and release of pro-inflammatory cytokines [50]. In addition, other suggested anti-AD of naringenin were seen in a series of studies [51–55].

On the other hand, ellagitannin-rich food extracts were found essential for both preventing and treating neurological disorders including Alzheimer's disease (AD). Urolithins, the intestinal microbial metabolites produced from ellagitannin- and ellagic-acid-containing foods, with more bioavailability than their precursors, contribute significantly to the beneficial properties attributed to these polyphenolic compounds. The potential mechanisms of urolithins have been investigated based on in vitro and in vivo tests in several studies. These studies support the positive effects of urolithins in the treatment of several diseases, including Alzheimer's disease, type 2 diabetes mellitus, liver disease, cardiovascular disease, and various cancers [56,57].

In previous research, *P. emblica* fruit methanol extract was found to be strongly active in inhibiting AChE (IC₅₀ 53.88 µg/mL) and BuChE (IC₅₀ 65.12 µg/mL) [48]. The *P. emblica* fruit polyphenols exhibited strong inhibition of AChE (IC₅₀ 0.2186 ± 0.0416 mg/mL) and BuChE (IC₅₀ 0.0542 ± 0.0054 mg/mL), and strong antioxidant capacities in scavenging free radicals [58]. Individual molecules, myricetin, quercetin, fisetin, and gallic acid, isolated from *P. emblica*, exerted low docking scores and strong inhibition ability on AChE with IC₅₀ values of 0.1974 ± 0.0047, 0.2589 ± 0.0131, 1.0905 ± 0.0598, and 1.503 ± 0.0728 mM, respectively [59]. In animal models, the fruit extracts have demonstrated protective benefits on organs/tissues against damages brought on by chemicals, stressors, and aging [60]. These outcomes support our findings and highlight the potential of *P. emblica* as a source of bioactive components.

Furthermore, investigation of Amla as a source of nutraceuticals revealed high vitamin C (ascorbic acid) and E (α-tocopherol) (Table 4) and mineral (Zn, Fe, K, and Na) content (Table 5). The vitamin C content in 100 g of fruit is 4.7 times the recommended dietary allowance, while vitamin E content in 100 g of leaves is 0.78% the recommended dietary allowance of vitamins [47]. Vitamin C and E are both antioxidants food ingredients that are established to have a neuroprotective impact by either lowering or avoiding oxidative damage [61]. Vitamin C is a necessary food for humans and serves as a redox buffering that can lower reactive oxygen species and so neutralize them. It is a crucial cofactor and electron donor for enzymes involved in a wide range of biological processes, including stimulating the immune system, producing collagen, hormones, and neurotransmitters, regulating cell division and growth, and removing heavy metals from the body [62]. A lipid soluble vitamin E is assumed to have neuroprotective effects by either lowering or avoiding oxidative damage through preventing the spread of lipid radicals and stops lipid peroxidation chain reactions in cellular membranes [63]. In summary, even though Alzheimer's disease cannot be reversed or cured, exploring *P. emblica* as a functional food

rich in acetylcholinesterase inhibitors would be a beneficial treatment option for problems with memory, cognition, and other mental functions.

The numerous polyphenolics (1–11) in addition to the high content of vitamins C and E with potent antioxidants point to the possibility that antioxidative activity is one of the *P. emblica* biological mechanisms underpinning Alzheimer's disease, which makes *P. emblica* a useful functional food with neuroprotective properties.

Results of antimicrobial screening of Amla leaves and fruit extracts (Table 17) revealed superior antimicrobial activity of leaves over the fruits' tested extract. The active molecules were accumulated mainly in the EtOAc and BuOH subextracts. The most sensitive bacterial species (exhibiting a wide inhibition zone) were *B. subtilis*, *S. aureus*, and *P. aeruginosa*, whereas the most sensitive fungal species was *Candida albicans*. Among the isolated compounds, corilagin (7) inhibited the growth of *E. coli*, *S. aureus*, and *C. albicans*. It exhibited membrane permeability disruption of *E. coli* and *C. albicans*, but acted on extracellular fibrinogen-binding protein, the response regulator SaeR protein, and sensor kinase SaeS of *S. aureus* [64]. Further, the reported antimicrobial activity of several isolated compounds, including gallic acid (1) [65], flavogallonic acid bislactone (6) [22,66], ethyl gallate (9) [67,68], and urolithin M5 (9) [69], against a broad spectrum of bacterial and viral species also emphasizes our antimicrobial findings (Table 17).

5. Conclusions

Oxidative stress is a key player in the pathophysiology of diseases such as atherosclerosis, cancer, Parkinson's, and Alzheimer's. Lower overall serum antioxidant components decrease the antioxidant capacity of the body. Functional foods or nutraceuticals have the capacity to function as natural antioxidants. Consuming such nutraceuticals in moderation helps keep the redox state steady and thus reduce oxidative stress damage. Our herein findings highlight *P. emblica* as an affordable source rich in natural vitamins, minerals, and polyphenolic compounds. Our findings from biological studies suggest that these components may integrate together to mitigate oxidative damage, treat microbial infections, and alleviate Alzheimer's symptoms by acetylcholinesterase inhibition.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/metabo13091013/s1>, Figure S1. ^1H NMR spectrum of compound 1 (DMSO- d_6 , 400 MHz); Figure S2. ^{13}C NMR spectrum of compound 1 (DMSO- d_6 , 100 MHz); Figure S3. ^1H NMR spectrum of compound 2 (CD_3OD , 400 MHz); Figure S4. DPTQ NMR spectrum of compound 2 (CD_3OD , 100 MHz); Figure S5. ^1H NMR spectrum of compound 3 [acetone- d_6 / D_2O , 9/1, v/v , 600 MHz]; Figure S6. ^{13}C NMR spectrum of compound 3 [acetone- d_6 / D_2O , 9/1, v/v , 151 MHz]; Figure S7. HSQC spectrum of compound 3 [acetone- d_6 / D_2O , 9/1, v/v , 600 MHz]; Figure S8. HMBC spectrum of compound 3 [acetone- d_6 / D_2O , 9/1, v/v , 600 MHz]; Figure S9. ^1H NMR spectrum of compound 4 [acetone- d_6 / D_2O , 9/1, v/v , 600 MHz]; Figure S10. ^{13}C NMR spectrum of compound 4 [acetone- d_6 / D_2O , 9/1, v/v , 151 MHz]; Figure S11. ^1H - ^1H COSY spectrum of compound 4 [acetone- d_6 / D_2O , 9/1, v/v , 600 MHz]; Figure S12. HSQC spectrum of compound 4 [acetone- d_6 / D_2O , 9/1, v/v , 600 MHz]; Figure S13. HMBC spectrum of compound 4 [acetone- d_6 / D_2O , 9/1, v/v , 600 MHz]; Figure S14. ^1H NMR spectrum of compound 5 [acetone- d_6 / D_2O , 9/1, v/v , 600 MHz]; Figure S15. ^1H - ^1H COSY spectrum of compound 5 [acetone- d_6 / D_2O , 9/1, v/v , 600 MHz]; Figure S16. ^1H NMR spectrum of compound 6 [acetone- d_6 / D_2O , 9/1, v/v , 600 MHz]; Figure S17. ^{13}C NMR spectrum of compound 6 [acetone- d_6 / D_2O , 9/1, v/v , 151 MHz]; Figure S18. HSQC spectrum of compound 6 [acetone- d_6 / D_2O , 9/1, v/v , 600 MHz]; Figure S19. HMBC spectrum of compound 6 [acetone- d_6 / D_2O , 9/1, v/v , 600 MHz]; Figure S20. ^1H NMR spectrum of compound 7 [acetone- d_6 / D_2O , 9/1, v/v , 600 MHz]; Figure S21. ^1H - ^1H COSY spectrum of compound 7 [acetone- d_6 / D_2O , 9/1, v/v , 600 MHz]; Figure S22. ^{13}C NMR spectrum of compound 7 [acetone- d_6 / D_2O , 9/1, v/v , 151 MHz]; Figure S23. HSQC spectrum of compound 7 [acetone- d_6 / D_2O , 9/1, v/v , 600 MHz]; Figure S24. HMBC spectrum of compound 7 [acetone- d_6 / D_2O , 9/1, v/v , 600 MHz]; Figure S25. ^1H NMR spectrum of compound 8 [acetone- d_6 / D_2O , 9/1, v/v , 600 MHz]; Figure S26. ^{13}C NMR spectrum of compound 8 [acetone- d_6 / D_2O , 9/1, v/v , 151 MHz]; Figure S27. HSQC spectrum of compound 8 [acetone- d_6 / D_2O , 9/1, v/v , 600 MHz]; Figure S28. HMBC spectrum of compound 8 [acetone- d_6 / D_2O , 9/1, v/v , 600 MHz];

Figure S29. ^1H NMR spectrum of compound **9** [acetone- d_6 /D $_2$ O, 9/1, v/v , 600 MHz]; Figure S30. ^{13}C NMR spectrum of compound **9** [acetone- d_6 /D $_2$ O, 9/1, v/v , 151 MHz]; Figure S31. ^1H NMR spectrum of compound **10** [acetone- d_6 /D $_2$ O, 9/1, v/v , 600 MHz]; Figure S32. ^1H - ^1H COSY spectrum of compound **10** [acetone- d_6 /D $_2$ O, 9/1, v/v , 600 MHz]; Figure S33. ^{13}C NMR spectrum of compound **10** [acetone- d_6 /D $_2$ O, 9/1, v/v , 151 MHz]; Figure S34. HSQC spectrum of compound **10** [acetone- d_6 /D $_2$ O, 9/1, v/v , 600 MHz]; Figure S35. HMBC spectrum of compound **10** [acetone- d_6 /D $_2$ O, 9/1, v/v , 600 MHz]; Figure S36. ^1H NMR spectrum of compound **11** CD $_3$ OD, 100 MHz); Figure S37. ^{13}C NMR spectrum of compound **11** (CD $_3$ OD, 100 MHz).

Author Contributions: Conceptualization, M.A.A.O., S.F.A., M.H.H. and M.A.E.-S.; methodology, M.A.A.O., A.H.H., M.H.H., D.E.A. and M.A.E.-S.; software, A.H.H., A.A.A.A. and O.S.A.; validation, D.E.A.; formal analysis, M.A.A.O., A.H.H. and D.E.A.; investigation, M.A.A.O., A.H.H. and D.E.A.; resources, M.A.A.O., A.A.A.A. and O.S.A.; data curation, A.A.A.A., O.S.A. and D.E.A.; writing—original draft preparation, M.A.A.O., A.H.H., A.A.A.A., O.S.A. and D.E.A.; writing—review and editing, M.A.A.O., A.H.H. and T.H.; visualization, A.A.A.A., O.S.A. and M.A.A.O.; supervision, S.F.A., M.H.H. and M.A.E.-S.; project administration, M.A.A.O. and D.E.A.; funding acquisition, M.A.A.O. and D.E.A. All authors have read and agreed to the published version of the manuscript.

Funding: The authors are thankful to the Deanship of Scientific Research at Najran University, Saudi Arabia, for funding this research under the National Research Priority Funding Program NU/NRP/MRC/12/1.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Raw NMR data spectra are available with the corresponding author and ready to supply upon request.

Acknowledgments: The authors are thankful to the Deanship of Scientific Research at Najran University, Saudi Arabia, for funding this research under the National Research Priority Funding Program NU/NRP/MRC/12/1.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Singh, B.; Uniyal, A.; Rawat, J.; Rana, D. Estimation of genetic variability in *Phyllanthus emblica* L.—Towards a contribution in sustainable rural development. *J. Hortic. For.* **2012**, *4*, 92–95. [[CrossRef](#)]
2. Barthakur, N.; Arnold, N. Chemical analysis of the emblic (*Phyllanthus emblica* L.) and its potential as a food source. *Sci. Hortic.* **1991**, *47*, 99–105. [[CrossRef](#)]
3. Ames, B.N.; Shigenaga, M.K.; Hagen, T.M. Oxidants, antioxidants, and the degenerative diseases of aging. *Proc. Natl. Acad. Sci. USA* **1993**, *90*, 7915–7922. [[CrossRef](#)] [[PubMed](#)]
4. Mal, A.; Meena, D.S. *Phyllanthus emblica*: A Herbal Remedy for Healthy Life. *ECS Trans.* **2022**, *107*, 3199. [[CrossRef](#)]
5. Saini, R.; Sharma, N.; Oladeji, O.S.; Sourirajan, A.; Dev, K.; Zengin, G.; El-Shazly, M.; Kumar, V. Traditional uses, bioactive composition, pharmacology, and toxicology of *Phyllanthus emblica* fruits: A comprehensive review. *J. Ethnopharmacol.* **2022**, *282*, 114570. [[CrossRef](#)] [[PubMed](#)]
6. Kim, H.J.; Yokozawa, T.; Kim, H.Y.; Tohda, C.; Rao, T.P.; Juneja, L.R. Influence of amla (*Emblia officinalis* Gaertn.) on hypercholesterolemia and lipid peroxidation in cholesterol-fed rats. *J. Nutr. Sci. Vitaminol.* **2005**, *51*, 413–418. [[CrossRef](#)] [[PubMed](#)]
7. Talreja, S.; Kumari, S.; Srivastava, P.; Pandey, S. A complete pharmacognostic review on amla. *World. J. Pharm. Pharm. Sci.* **2021**, *8*, 622–637. [[CrossRef](#)]
8. Gul, M.; Liu, Z.W.; Rabail, R.; Faheem, F.; Walayat, N.; Nawaz, A.; Shabbir, M.A.; Munekata, P.E.; Lorenzo, J.M.; Aadil, R.M. Functional and nutraceutical significance of Amla (*Phyllanthus emblica* L.): A Review. *Antioxidants* **2022**, *11*, 816. [[CrossRef](#)]
9. Kudva, A.K.; Baliga, M.S.; Raghu, S.V. Pharmacological application of *Phyllanthus emblica* as therapeutics in Alzheimer's disease. In *Functional Foods and Therapeutic Strategies for Neurodegenerative Disorders*; Springer Nature: Singapore, 2022; pp. 1–63. [[CrossRef](#)]
10. Sabu, M.; Kuttan, R. Anti-diabetic activity of medicinal plants and its relationship with their antioxidant property. *J. Ethnopharmacol.* **2002**, *81*, 155–160. [[CrossRef](#)]
11. Mirunalini, S.; Krishnaveni, M. Therapeutic potential of *Phyllanthus emblica* (amla): The ayurvedic wonder. *J. Basic Clin. Physiol. Pharmacol.* **2010**, *21*, 93–105. [[CrossRef](#)]
12. Nain, P.; Saini, V.; Sharma, S.; Nain, J. Antidiabetic and antioxidant potential of *Emblia officinalis* Gaertn. leaves extract in streptozotocin-induced type-2 diabetes mellitus (T2DM) rats. *J. Ethnopharmacol.* **2012**, *142*, 65–71. [[CrossRef](#)] [[PubMed](#)]

13. Ngamkitidechakul, C.; Jaijoy, K.; Hansakul, P.; Soonthornchareonnon, N.; Sireeratawong, S. Antitumour effects of *Phyllanthus emblica* L.: Induction of cancer cell apoptosis and inhibition of in vivo tumour promotion and in vitro invasion of human cancer cells. *Phytother. Res.* **2010**, *24*, 1405–1413. [CrossRef] [PubMed]
14. Xiang, Y.-F.; Ju, H.-Q.; Li, S.; Zhang, Y.-J.; Yang, C.-R.; Wang, Y.-F. Effects of 1,2,4,6-tetra-O-galloyl- β -D-glucose from *P. emblica* on HBsAg and HBeAg secretion in HepG2. 2.15 cell culture. *Viol. Sin.* **2010**, *25*, 375–380. [CrossRef] [PubMed]
15. Jose, J.K.; Kuttan, G.; Kuttan, R. Antitumour activity of *Emblia officinalis*. *J. Ethnopharmacol* **2001**, *75*, 65–69. [CrossRef] [PubMed]
16. Faried, A.; Kurnia, D.; Faried, L.; Usman, N.; Miyazaki, T.; Kato, H.; Kuwano, H. Anticancer effects of gallic acid isolated from Indonesian herbal medicine, *Phaleria macrocarpa* (Scheff.) Boerl, on human cancer cell lines. *Int. J. Oncol.* **2007**, *30*, 605–613. [CrossRef] [PubMed]
17. Osamudiamen, P.M.; Oluremi, B.B.; Oderinlo, O.O.; Aiyelaagbe, O.O. Trans-resveratrol, piceatannol and gallic acid: Potent polyphenols isolated from *Mezoneuron benthamianum* effective as anticaries, antioxidant and cytotoxic agents. *Sci. Afr.* **2020**, *7*, e00244. [CrossRef]
18. Sissi, H.I.E.; Saleh, N.A.M.; El Nnegoumy, S.I.; Wagner, H.; Iyengar, M.A.; Seligmann, O. Prunin-O-6''-gallat, aus *Acacia arnesiana*. *Phytochemistry* **1974**, *13*, 2843–2844. [CrossRef]
19. Ye, G.; Peng, H.; Fan, M.; Huang, C.G. Ellagic acid derivatives from the stem bark of *Dipentodon sinicus*. *Chem. Nat. Compd.* **2007**, *43*, 125–127. [CrossRef]
20. Nonaka, G.; Nishioka, I. Tannins and related compounds. X. Rhubarb (2): Isolation and structures of a glycerol gallate, gallic acid glucoside gallates, galloylglucoses and isolindleyin. *Chem. Pharm. Bull.* **1983**, *31*, 1652–1658. [CrossRef]
21. Farag, S.F. Polyphenolic compounds from the leaves of *Schinus terebinthifolius* Raddi. *Bull. Pharm. Sci. Assiut* **2008**, *31*, 319–329. [CrossRef]
22. Mohieldin, E.A.M.; Muddathir, A.M.; Yamauchi, K.; Mitsunaga, T. Anti-caries activity of selected Sudanese medicinal plants with emphasis on *Terminalia laxiflora*. *Rev. Bras. Farm.* **2017**, *27*, 611–618. [CrossRef]
23. Thitilertdecha, N.; Teerawutgulrag, A.; Kilburn, J.D.; Rakariyatham, N. Identification of major phenolic compounds from *Nephelium lappaceum* L., their antioxidant activities. *Molecules* **2010**, *15*, 1453–1465. [CrossRef] [PubMed]
24. Kochumadhavan, A.; Mangal, P.; Kumar, L.S.; Meenakshi, B.M.; Venkanna, B.U.; Muguli, G. Corilagin: First time isolation from the whole plant of *Phyllanthus maderaspatensis* L. *Pharmacogn. Commun.* **2019**, *9*, 135–138. [CrossRef]
25. Leela, V.; Saraswathy, A. Isolation and phytoconstituents of *Acacia leucophloea* (Roxeb) willd. *Int. Res. J. Pharm.* **2013**, *4*, 107–109. [CrossRef]
26. Dao, N.T.; Jang, Y.; Kim, M.; Nguyen, H.H.; Pham, D.Q.; Le Dang, Q.; Van Nguyen, M.; Yun, B.-S.; Pham, Q.M.; Kim, J.-C.; et al. Chemical constituents and anti-influenza viral activity of the leaves of Vietnamese plant *Elaeocarpus tonkinensis*. *Rec. Nat. Prod.* **2019**, *13*, 171–180. [CrossRef]
27. Fons, F.; Rapior, S.; Gueiffier, A.; Roussel, J.L.; Gargadennec, A.; Andary, C. (E)-p-coumaroyl-1-O- β -D-glucopyranoside accumulation in roots of *Plantago lanceolata* cultures. *Acta Bot. Gall.* **1998**, *145*, 249–255. Available online: <https://hal.umontpellier.fr/hal-02262396> (accessed on 19 July 2023).
28. Xiang, Y.; Pei, Y.; Qu, C.; Lai, Z.; Ren, Z.; Yang, K.; Xiong, S.; Zhang, Y.; Yang, C.; Wang, D.; et al. In vitro anti-herpes simplex virus activity of 1,2,4,6-Tetra-O-galloyl- β -D-glucose from *Phyllanthus emblica* L. (Euphorbiaceae). *Phytother. Res.* **2011**, *25*, 975–982. [CrossRef]
29. Velioglu, Y.; Mazza, G.; Gao, L.; Oomah, B.D. Antioxidant activity and total phenolics in selected fruits, vegetables, and grain products. *J. Agric. Food Chem.* **1998**, *46*, 4113–4117. [CrossRef]
30. Baba, S.A.; Malik, S.A. Determination of total phenolic and flavonoid content, antimicrobial and antioxidant activity of a root extract of *Arisaema jacquemontii* Blume. *J. Taibah Univ. Sci.* **2015**, *9*, 449–454. [CrossRef]
31. Burden, T.P.; Robinson, W.C. Formation of complexes between protein and tannin acid. *J. Agric. Food Chem.* **1981**, *1*, 77–82. [CrossRef]
32. Kall, M.A.; Andersen, C. Improved method for simultaneous determination of ascorbic acid and dehydroascorbic acid, isoascorbic acid and dehydroisoascorbic acid in food and biological samples. *J. Chromatogr. B Biomed. Sci. Appl.* **1999**, *730*, 101–111. [CrossRef] [PubMed]
33. Lim, H.; Woo, S.; Kim, H.S.; Jong, S.K.; Lee, J. Comparison of extraction methods for determining tocopherols in soybeans. *Eur. J. Lipid Sci. Technol.* **2007**, *109*, 1124–1127. [CrossRef]
34. Tokalioğlu, Ş. Determination of trace elements in commonly consumed medicinal herbs by ICP-MS and multivariate analysis. *Food Chem.* **2012**, *134*, 2504–2508. [CrossRef] [PubMed]
35. Mensor, L.L.; Menezes, F.S.; Leitão, G.G.; Reis, A.S.; Santos, T.C.D.; Coube, C.S.; Leitão, S.G. Screening of Brazilian plant extracts for antioxidant activity by the use of DPPH free radical method. *Phytother. Res.* **2001**, *15*, 127–130. [CrossRef] [PubMed]
36. Maidment, C.; Dembny, Z.; King, P. Investigations into the anti-bacterial properties of garlic using the disc assay method. *J. Biol. Educ.* **1998**, *32*, 162–165. [CrossRef]
37. Vina, A. Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *Trott, Oleg; Olson, Arthur, J. J. Comput. Chem.* **2010**, *31*, 455–461. [CrossRef]
38. Anbukarasi, K.; Xavier, S.; Hasan, A.H.; Er, Y.L.; Jamalis, J.; Sebastian, S.; Periandy, S. DFT and molecular docking analysis of newly synthesized compound (2E)-3-[3-(benzyloxy) phenyl]-1-(4'-chlorophe-Nyl)-2-propen-1-One [Bpclpo]. *Curr. Phys. Chem.* **2023**, *13*, 37–74. [CrossRef]

39. Hussien, N.H.; Hasan, A.H.; Jamalis, J.; Shakya, S.; Chander, S.; Kharkwal, H.; Murugesan, S.; Bastikar, V.A.; Gupta, P.P. Potential inhibitory activity of phytoconstituents against black fungus: In silico ADMET, molecular docking and MD simulation studies. *Comput. Toxicol.* **2022**, *24*, 100247. [CrossRef]
40. Salih, R.H.H.; Hasan, A.H.; Hussein, A.J.; Samad, M.K.; Shakya, S.; Jamalis, J.; Hawaiz, F.E.; Pratama, M.R.F. One-pot synthesis, molecular docking, ADMET, and DFT studies of novel pyrazolines as promising SARS-CoV-2 main protease inhibitors. *Res. Chem. Intermed.* **2022**, *48*, 4729–4751. [CrossRef]
41. Morris, G.M.; Goodsell, D.S.; Halliday, R.S.; Huey, R.; Hart, W.E.; Belew, R.K.; Olson, A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. *J. Comput. Chem.* **1998**, *19*, 1639–1662. [CrossRef]
42. Hasan, A.H.; Shakya, S.; Hussain, F.H.; Murugesan, S.; Chander, S.; Pratama, M.R.F.; Jamil, S.; Das, B.; Biswas, S.; Jamalis, J. Design, synthesis, anti-acetylcholinesterase evaluation and molecular modelling studies of novel coumarin-chalcone hybrids. *J. Biomol. Struct. Dyn.* **2022**, 1–13. [CrossRef] [PubMed]
43. Hasan, A.H.; Murugesan, S.; Amran, S.I.; Chander, S.; Alanazi, M.M.; Hadda, T.B.; Shakya, S.; Pratama, M.R.F.; Das, B.; Biswas, S. Novel thiophene Chalcones-Coumarin as acetylcholinesterase inhibitors: Design, synthesis, biological evaluation, molecular docking, ADMET prediction and molecular dynamics simulation. *Bioorg. Chem.* **2022**, *119*, 105572. [CrossRef] [PubMed]
44. Hasan, A.H.; Yusof, F.S.M.; Kamarudin, N.A.; Murugesan, S.; Shakya, S.; Jamalis, J. Synthesis, anti-acetylcholinesterase evaluation, molecular docking and molecular dynamics simulation of novel Psoralen derivatives. *Curr. Org. Synth.* **2023**, *21*, 61–77. [CrossRef]
45. Salih, R.H.H.; Hasan, A.H.; Hussien, N.H.; Hawaiz, F.E.; Hadda, T.B.; Jamalis, J.; Almalki, F.A.; Adeyinka, A.S.; Coetzee, L.C.C.; Oyebamiji, A.K. Thiazole-pyrazoline hybrids as potential antimicrobial agent: Synthesis, biological evaluation, molecular docking, DFT studies and POM analysis. *J. Mol. Struct.* **2023**, *1282*, 135191. [CrossRef]
46. Chandler, S. The nutritional value of bananas. In *Bananas and Plantains*; Springer: Dordrecht, The Netherlands, 1995; pp. 468–480. Available online: https://link.springer.com/chapter/10.1007/978-94-011-0737-2_16 (accessed on 19 July 2023).
47. Palmer, S. Recommended dietary allowances. *Eur. J. Clin. Nutr.* **1990**, *44* (Suppl. S2), 13–21. [PubMed]
48. Biswas, K.; Islam, A.; Sharmin, T.; Biswas, P.K. In-vitro cholinesterase inhibitory activity of dry fruit extract of *Phyllanthus emblica* relevant to the treatment of Alzheimer's disease. *J. Phytopharm.* **2015**, *4*, 5–8. [CrossRef]
49. Heo, H.J.; Kim, M.J.; Lee, J.M.; Choi, S.J.; Cho, H.Y.; Hong, B.; Kim, H.K.; Kim, E.; Shin, D.H. Naringenin from *Citrus junos* has an inhibitory effect on acetylcholinesterase and a mitigating effect on amnesia. *Dement. Geriatr. Cogn. Disord.* **2004**, *17*, 151–157. [CrossRef]
50. Umukoro, S.; Kalejaye, H.A.; Ben-Azu, B.; Ajayi, A.M. Naringenin attenuates behavioral derangements induced by social defeat stress in mice via inhibition of acetylcholinesterase activity, oxidative stress and release of pro-inflammatory cytokines. *Biomed. Pharmacother.* **2018**, *105*, 714–723. [CrossRef] [PubMed]
51. Chtourou, Y.; Slima, A.B.; Gdoura, R.; Fetoui, H. Naringenin mitigates iron-induced anxiety-like behavioral impairment, mitochondrial dysfunctions, ectonucleotidases and acetylcholinesterase alteration activities in rat hippocampus. *Neurochem. Res.* **2015**, *40*, 1563–1575. [CrossRef]
52. Sachdeva, A.K.; Kuhad, A.; Chopra, K. Naringin ameliorates memory deficits in experimental paradigm of Alzheimer's disease by attenuating mitochondrial dysfunction. *Pharmacol. Biochem. Behav.* **2014**, *127*, 101–110. [CrossRef]
53. Zaki, H.F.; Abd-El-Fattah, M.A.; Attia, A.S. Naringenin protects against scopolamine-induced dementia in rats. *Bull. Fac. Pharm. Cairo Univ.* **2014**, *52*, 15–25. [CrossRef]
54. Haider, S.; Liaquat, L.; Ahmad, S.; Batool, Z.; Siddiqui, R.A.; Tabassum, S.; Shahzad, S.; Rafiq, S.; Naz, N. Naringenin protects AlCl₃/D-galactose induced neurotoxicity in rat model of AD via attenuation of acetylcholinesterase levels and inhibition of oxidative stress. *PLoS ONE* **2020**, *15*, e0227631. [CrossRef] [PubMed]
55. Khajevand-Khazaei, M.R.; Ziaee, P.; Motevalzadeh, S.A.; Rohani, M.; Afshin-Majid, S.; Baluchnejadmojarad, T.; Roghani, M. Naringenin ameliorates learning and memory impairment following systemic lipopolysaccharide challenge in the rat. *Eur. J. Pharmacol.* **2018**, *826*, 114–122. [CrossRef] [PubMed]
56. García-Villalba, R.; Tomás-Barberán, F.A.; Iglesias-Aguirre, C.E.; Giménez-Bastida, J.A.; González-Sarriás, A.; Selma, M.V.; Espín, J.C. Ellagitannins, urolithins, and neuroprotection: Human evidence and the possible link to the gut microbiota. *Mol. Asp. Med.* **2023**, *89*, 101109. [CrossRef] [PubMed]
57. Hasheminezhad, S.H.; Boozari, M.; Iranshahi, M.; Yazarlu, O.; Sahebkar, A.; Hasanpour, M.; Iranshahi, M. A mechanistic insight into the biological activities of urolithins as gut microbial metabolites of ellagitannins. *Phytother. Res.* **2022**, *36*, 112–146. [CrossRef] [PubMed]
58. Wu, M.; Cai, J.; Fang, Z.; Li, S.; Huang, Z.; Tang, Z.; Luo, Q.; Chen, H. The composition and anti-aging activities of polyphenol extract from *Phyllanthus emblica* L. fruit. *Nutrients* **2022**, *14*, 857. [CrossRef]
59. Wu, M.; Liu, M.; Wang, F.; Cai, J.; Luo, Q.; Li, S.; Zhu, J.; Tang, Z.; Fang, Z.; Wang, C. The inhibition mechanism of polyphenols from *Phyllanthus emblica* Linn. fruit on acetylcholinesterase: A interaction, kinetic, spectroscopic, and molecular simulation study. *Food Res. Int.* **2022**, *158*, 111497. [CrossRef] [PubMed]
60. Yang, B.; Liu, P. Composition and biological activities of hydrolyzable tannins of fruits of *Phyllanthus emblica*. *J. Agric. Food Chem.* **2014**, *62*, 529–541. [CrossRef]
61. Hasanein, P.; Shahidi, S. Effects of combined treatment with vitamins C and E on passive avoidance learning and memory in diabetic rats. *Neurobiol. Learn. Mem.* **2010**, *93*, 472–478. [CrossRef]

62. Jodh, R.; Tawar, M.; Mude, G.; Fasate, A.; Sutane, R.; Patanray, P. An updated review on vitamin C—An excellent drug having a great scavenging property. *Asian J. Pharm. Clin. Res.* **2023**, *13*, 25–30. [[CrossRef](#)]
63. Juszczyk, G.; Mikulska, J.; Kasperek, K.; Pietrzak, D.; Mrozek, W.; Herbet, M. Chronic stress and oxidative stress as common factors of the pathogenesis of depression and Alzheimer’s disease: The role of antioxidants in prevention and treatment. *Antioxidants* **2021**, *10*, 1439. [[CrossRef](#)] [[PubMed](#)]
64. Li, N.; Luo, M.; Fu, Y.J.; Zu, Y.G.; Wang, W.; Zhang, L.; Yao, L.P.; Zhao, C.J.; Sun, Y. Effect of corilagin on membrane permeability of *Escherichia coli*, *Staphylococcus aureus* and *Candida albicans*. *Phytother. Res.* **2013**, *27*, 1517–1523. [[CrossRef](#)] [[PubMed](#)]
65. Sorrentino, E.; Succi, M.; Tipaldi, L.; Pannella, G.; Maiuro, L.; Sturchio, M.; Coppola, R.; Tremonte, P. Antimicrobial activity of gallic acid against food-related *Pseudomonas* strains and its use as biocontrol tool to improve the shelf life of fresh black truffles. *Int. J. Food Microbiol.* **2018**, *266*, 183–189. [[CrossRef](#)] [[PubMed](#)]
66. Muddathir, A.M.; Yamauchi, K.; Mitsunaga, T. Anti-acne activity of tannin-related compounds isolated from *Terminalia laxiflora*. *J. Wood Sci.* **2013**, *59*, 426–431. [[CrossRef](#)]
67. Passos, M.R.; Almeida, R.S.; Lima, B.O.; de Souza Rodrigues, J.Z.; de Macêdo Neres, N.S.; Pita, L.S.; Marinho, P.D.O.F.; Santos, I.A.; da Silva, J.P.; Oliveira, M.C.; et al. Anticariogenic activities of *Libidibia ferrea*, gallic acid and ethyl gallate against *Streptococcus mutans* in biofilm model. *J. Ethnopharmacol.* **2021**, *274*, 114059. [[CrossRef](#)] [[PubMed](#)]
68. Chen, L.; Chen, X.; Bai, Y.; Zhao, Z.-N.; Cao, Y.-F.; Liu, L.-K.; Jiang, T.; Hou, J. Inhibition of *Escherichia coli* nitroreductase by the constituents in *Syzygium aromaticum*. *Chin. J. Nat. Med.* **2022**, *20*, 506–517. [[CrossRef](#)] [[PubMed](#)]
69. Xiao, M.; Cao, F.; Huang, T.; Tang, Y.S.; Zhao, X.; Shaw, P.C. Urolithin M5 from the leaves of *Canarium album* (Lour.) DC. inhibits influenza virus by targeting neuraminidase. *Molecules* **2022**, *27*, 5724. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.